Research Division, Manmohan Memorial Institute of Health Sciences, Soalteemod, Kathmandu, Nepal. Department of Pharmacy, Manmohan Memorial Institute of Health Sciences, Soalteemode, Kathmandu, Nepal. and Fellow, CVD Translational Research Program, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
Department of Community Programs, Dhulikhel Hospital-Kathmandu University Hospital, Kavrepalanchowk, Nepal.
Kathmandu Univ Med J (KUMJ). 2021;19(75):18-29.
Background Medical Products and Technologies is a key component of the health system. Quality medicines and efficient management of the medical products can secure effective cardiovascular diseases management. Objective To collate information and identify strengths, weaknesses, opportunities and threats (SWOT) associated with medical products and technology component for cardiovascular disease management in Nepal. Method This study is a part of a larger rapid assessment of Nepal's health system for cardiovascular disease management and based on The Health System Assessment Approach: A How-To Manual (USAID). The authors conducted a desk review of documents related to the WHO "medical product and technology" building block component and key informant interviews using a pre-tested interview protocol. The first eight interviews were transcribed verbatim and analysed inductively to generate a codebook; and the remaining, transcribed and deductively coded based on the codebook. Findings were categorised into relevant topical area and SWOT components. Result Nepal has laws and provisions for medicine regulation, pharmacovigilance, post marketing surveillance, registration and licensing provisions for pharmacy industries/ outlets, essential medicine lists and national formulary. These provisions also apply to medicines used for cardiovascular diseases. The challenge however, is the lack of effective implementation and monitoring, due to shortages of technical workforce and state of art information and technologies. Information on pharmaceutical expenditures for cardiovascular disease management is scarce; there are no standard national level guidelines that are consistently used to manage cardiovascular diseases in health facilities. Conclusion There are limited provisions and information on medical products for cardiovascular disease management in Nepal, and a need to strengthen existing provisions for medicine regulations and surveillance.
医疗产品和技术是医疗体系的重要组成部分。高质量的药品和有效的医疗产品管理能够确保心血管疾病管理的有效性。
整理信息并确定尼泊尔心血管疾病管理中与医疗产品和技术相关的优势、劣势、机遇和威胁(SWOT)。
本研究是对尼泊尔心血管疾病管理卫生系统快速评估的一部分,基于《卫生系统评估方法:操作手册》(USAID)。作者对与世界卫生组织“医疗产品和技术”构建模块相关的文件进行了桌面审查,并使用预先测试的访谈协议对关键知情人进行了访谈。前八次访谈进行了逐字逐句的转录,并进行了归纳分析以生成代码本;其余访谈根据代码本进行了转录和演绎编码。研究结果被归类为相关主题领域和 SWOT 部分。
尼泊尔拥有针对药品监管、药物警戒、上市后监测、制药行业/药店注册和许可规定、基本药物清单和国家处方的法律和规定。这些规定也适用于用于心血管疾病的药物。然而,由于技术劳动力短缺以及缺乏先进的信息和技术,这些规定在执行和监测方面存在挑战。关于心血管疾病管理的药品支出信息匮乏;没有一致使用的标准国家层面指南来管理卫生机构中的心血管疾病。
尼泊尔在心血管疾病管理的医疗产品方面的规定和信息有限,需要加强药品监管和监测方面的现有规定。